Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 20,800 shares, a decline of 6.3% from the June 30th total of 22,200 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.4% of the shares of the company are short sold.

Aprea Therapeutics Stock Performance

Shares of APRE stock traded down $0.08 on Tuesday, hitting $3.92. The stock had a trading volume of 6,323 shares, compared to its average volume of 20,106. The firm has a market capitalization of $21.29 million, a price-to-earnings ratio of -1.14 and a beta of 1.04. The stock’s 50 day moving average is $4.26 and its 200-day moving average is $5.42. Aprea Therapeutics has a 52-week low of $2.95 and a 52-week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.11. The firm had revenue of $0.38 million for the quarter. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. Equities analysts expect that Aprea Therapeutics will post -2.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on APRE. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a report on Tuesday, May 14th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a report on Monday, June 24th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.